Global Information
회사소개 | 문의

레티노산 수용체 감마 : 파이프라인 리뷰

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 557376
페이지 정보 영문 75 Pages
가격
US $ 3,500 ₩ 3,984,400 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,968,800 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,953,200 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


레티노산 수용체 감마 : 파이프라인 리뷰 Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018
발행일: 2018년 08월 페이지 정보 : 영문 75 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

레티노산 수용체 감마(Retinoic Acid Receptor Gamma)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

레티노산 수용체 감마 : 개요

레티노산 수용체 감마 : 치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별
  • 기업에서 개발중인 제품

치료제 평가

  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • 3SBio Inc
  • Boehringer Ingelheim GmbH
  • Clementia Pharmaceuticals Inc
  • Galderma SA
  • Lee's Pharmaceutical Holdings Ltd
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Valeant Pharmaceuticals International Inc

약제 개요

휴지 상태인 제품

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.10.16

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indication, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by 3SBio Inc, H2 2018
  • Pipeline by Bausch Health Companies Inc, H2 2018
  • Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Pipeline by Clementia Pharmaceuticals Inc, H2 2018
  • Pipeline by Galderma SA, H2 2018
  • Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
  • Pipeline by Phosphagenics Ltd, H2 2018
  • Pipeline by Promius Pharma LLC, H2 2018
  • Pipeline by Sol-Gel Technologies Ltd, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

영문목차

Summary:

According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 21 molecules.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively.

Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Oncology, Ophthalmology, Respiratory, Gastrointestinal and Genetic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Multiple Hereditary Exostoses, Plaque Psoriasis (Psoriasis Vulgaris) and Retinopathy Of Prematurity.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
    • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Bausch Health Companies Inc
    • Boehringer Ingelheim GmbH
    • Clementia Pharmaceuticals Inc
    • Galderma SA
    • Lee's Pharmaceutical Holdings Ltd
    • Phosphagenics Ltd
    • Promius Pharma LLC
    • Sol-Gel Technologies Ltd
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
    • (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (adapalene + clindamycin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (benzoyl peroxide + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (benzoyl peroxide + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (clindamycin phosphate + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (halobetasol propionate + tazarotene) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (TPX-6001 + tretinoin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alitretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bexarotene + CD1530 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palovarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize RARG for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tretinoin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trifarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 18, 2018: FDA declines to approve Valeant's plaque psoriasis lotion
      • Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion
      • May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
      • Apr 20, 2018: Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
      • Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology
      • Feb 15, 2018: Sol-Gel's Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting
      • Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
      • Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
      • Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease
      • Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris
      • Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
      • Sep 05, 2017: Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
      • Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September
      • Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris
      • Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
La Merie Publishing
BCC Research